{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:57:35Z","timestamp":1778191055262,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00213-019-05353-6","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T17:02:32Z","timestamp":1566406952000},"page":"155-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat"],"prefix":"10.1007","volume":"237","author":[{"given":"Kathryn","family":"Lanza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Chemakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Lefkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"issue":"3","key":"5353_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448\u2013458","journal-title":"Mov Disord"},{"issue":"2","key":"5353_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1172\/JCI90132","volume":"127","author":"C Alcacer","year":"2017","unstructured":"Alcacer C, Andreoli L, Sebastianutto I, Jakobsson J, Fieblinger T, Cenci MA (2017) Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson\u2019s disease therapy. J Clin Invest 127(2):720\u2013734. \nhttps:\/\/doi.org\/10.1172\/JCI90132","journal-title":"J Clin Invest"},{"issue":"17","key":"5353_CR3","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1523\/JNEUROSCI.0837-12.2012","volume":"32","author":"C Alcacer","year":"2012","unstructured":"Alcacer C, Santini E, Valjent E, Gaven F, Girault JA, Herve D (2012) Galpha(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 32(17):5900\u20135910. \nhttps:\/\/doi.org\/10.1523\/JNEUROSCI.0837-12.2012","journal-title":"J Neurosci"},{"key":"5353_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.nbd.2014.12.008","volume":"74","author":"A Avalos-Fuentes","year":"2015","unstructured":"Avalos-Fuentes A, Albarran-Bravo S, Loya-Lopez S, Cortes H, Recillas-Morales S, Magana JJ et al (2015) Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca(2+) dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat. Neurobiol Dis 74:336\u2013346. \nhttps:\/\/doi.org\/10.1016\/j.nbd.2014.12.008","journal-title":"Neurobiol Dis"},{"issue":"1","key":"5353_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neuroscience.2008.07.016","volume":"156","author":"CJ Barnum","year":"2008","unstructured":"Barnum CJ, Eskow KL, Dupre K, Blandino P Jr, Deak T, Bishop C (2008) Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 156(1):30\u201341. \nhttps:\/\/doi.org\/10.1016\/j.neuroscience.2008.07.016","journal-title":"Neuroscience"},{"issue":"15","key":"5353_CR6","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1523\/JNEUROSCI.5884-08.2009","volume":"29","author":"A Berthet","year":"2009","unstructured":"Berthet A, Porras G, Doudnikoff E, Stark H, Cador M, Bezard E, Bloch B (2009) Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 29(15):4829\u20134835. \nhttps:\/\/doi.org\/10.1523\/JNEUROSCI.5884-08.2009","journal-title":"J Neurosci"},{"issue":"7","key":"5353_CR7","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","volume":"94","author":"R Bordet","year":"1997","unstructured":"Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 94(7):3363\u20133367","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"5353_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1046\/j.1460-9568.2000.00089.x","volume":"12","author":"R Bordet","year":"2000","unstructured":"Bordet R, Ridray S, Schwartz JC, Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12(6):2117\u20132123","journal-title":"Eur J Neurosci"},{"key":"5353_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fneur.2014.00242","volume":"5","author":"MA Cenci","year":"2014","unstructured":"Cenci MA (2014) Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 5:242. \nhttps:\/\/doi.org\/10.3389\/fneur.2014.00242","journal-title":"Front Neurol"},{"issue":"2","key":"5353_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","volume":"88","author":"JW Chang","year":"1999","unstructured":"Chang JW, Wachtel SR, Young D, Kang UJ (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson\u2019s disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88(2):617\u2013628","journal-title":"Neuroscience"},{"issue":"2","key":"5353_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord 20(2):224\u2013230. \nhttps:\/\/doi.org\/10.1002\/mds.20279","journal-title":"Mov Disord"},{"issue":"3","key":"5353_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ene.12318","volume":"21","author":"M Chondrogiorgi","year":"2014","unstructured":"Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S (2014) Dopamine agonist monotherapy in Parkinson\u2019s disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol 21(3):433\u2013440. \nhttps:\/\/doi.org\/10.1111\/ene.12318","journal-title":"Eur J Neurol"},{"issue":"9","key":"5353_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/mds.21292","volume":"22","author":"R Constantinescu","year":"2007","unstructured":"Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K, CALM-PD Inverstigators of the Parkinson Stuedy Group (2007) Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 22(9):1317\u20131319. \nhttps:\/\/doi.org\/10.1002\/mds.21292","journal-title":"Mov Disord"},{"key":"5353_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pbb.2016.01.004","volume":"142","author":"MM Conti","year":"2016","unstructured":"Conti MM, Goldenberg AA, Kuberka A, Mohamed M, Eissa S, Lindenbach D, Bishop C (2016) Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. Pharmacol Biochem Behav 142:64\u201371. \nhttps:\/\/doi.org\/10.1016\/j.pbb.2016.01.004","journal-title":"Pharmacol Biochem Behav"},{"key":"5353_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.017","volume":"77","author":"MM Conti","year":"2014","unstructured":"Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R et al (2014) Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 77:1\u20138. \nhttps:\/\/doi.org\/10.1016\/j.neuropharm.2013.09.017","journal-title":"Neuropharmacology"},{"issue":"7","key":"5353_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17460441.2016.1185413","volume":"11","author":"A Cortes","year":"2016","unstructured":"Cortes A, Moreno E, Rodriguez-Ruiz M, Canela EI, Casado V (2016) Targeting the dopamine D3 receptor: an overview of drug design strategies. Expert Opin Drug Discov 11(7):641\u2013664. \nhttps:\/\/doi.org\/10.1080\/17460441.2016.1185413","journal-title":"Expert Opin Drug Discov"},{"key":"5353_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neulet.2014.11.023","volume":"585","author":"SR Cote","year":"2015","unstructured":"Cote SR, Kuzhikandathil EV (2015) Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP\/p mouse model of Parkinson\u2019s disease. Neurosci Lett 585:33\u201337. \nhttps:\/\/doi.org\/10.1016\/j.neulet.2014.11.023","journal-title":"Neurosci Lett"},{"key":"5353_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.neuropharm.2012.11.032","volume":"67","author":"R Cruz-Trujillo","year":"2013","unstructured":"Cruz-Trujillo R, Avalos-Fuentes A, Rangel-Barajas C, Paz-Bermudez F, Sierra A, Escartin-Perez E et al (2013) D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat. Neuropharmacology 67:370\u2013378. \nhttps:\/\/doi.org\/10.1016\/j.neuropharm.2012.11.032","journal-title":"Neuropharmacology"},{"issue":"1","key":"5353_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76\u201389. \nhttps:\/\/doi.org\/10.1016\/j.bbr.2007.01.013","journal-title":"Behav Brain Res"},{"key":"5353_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.physbeh.2015.02.032","volume":"148","author":"TL Doremus-Fitzwater","year":"2015","unstructured":"Doremus-Fitzwater TL, Gano A, Paniccia JE, Deak T (2015) Male adolescent rats display blunted cytokine responses in the CNS after acute ethanol or lipopolysaccharide exposure. Physiol Behav 148:131\u2013144. \nhttps:\/\/doi.org\/10.1016\/j.physbeh.2015.02.032","journal-title":"Physiol Behav"},{"key":"5353_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.brainres.2007.05.005","volume":"1158","author":"KB Dupre","year":"2007","unstructured":"Dupre KB, Eskow KL, Negron G, Bishop C (2007) The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135\u2013143. \nhttps:\/\/doi.org\/10.1016\/j.brainres.2007.05.005","journal-title":"Brain Res"},{"issue":"7","key":"5353_CR22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/syn.20630","volume":"63","author":"KL Eskow","year":"2009","unstructured":"Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63(7):610\u2013620. \nhttps:\/\/doi.org\/10.1002\/syn.20630","journal-title":"Synapse"},{"key":"5353_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nbd.2018.09.018","volume":"121","author":"S Fanni","year":"2018","unstructured":"Fanni S, Scheggi S, Rossi F, Tronci E, Traccis F, Stancampiano R, de Montis MG, Devoto P, Gambarana C, Bortolato M, Frau R, Carta M (2018) 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Neurobiol Dis 121:120\u2013130. \nhttps:\/\/doi.org\/10.1016\/j.nbd.2018.09.018","journal-title":"Neurobiol Dis"},{"issue":"3","key":"5353_CR24","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s12035-014-8936-x","volume":"52","author":"D Farre","year":"2015","unstructured":"Farre D, Munoz A, Moreno E, Reyes-Resina I, Canet-Pons J, Dopeso-Reyes IG et al (2015) Stronger dopamine D1 receptor-mediated neurotransmission in dyskinesia. Mol Neurobiol 52(3):1408\u20131420. \nhttps:\/\/doi.org\/10.1007\/s12035-014-8936-x","journal-title":"Mol Neurobiol"},{"issue":"1","key":"5353_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1124\/mol.107.043885","volume":"74","author":"C Fiorentini","year":"2008","unstructured":"Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74(1):59\u201369. \nhttps:\/\/doi.org\/10.1124\/mol.107.043885","journal-title":"Mol Pharmacol"},{"issue":"9","key":"5353_CR26","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.euroneuro.2014.11.021","volume":"25","author":"C Fiorentini","year":"2015","unstructured":"Fiorentini C, Savoia P, Bono F, Tallarico P, Missale C (2015) The D3 dopamine receptor: from structural interactions to function. Eur Neuropsychopharmacol 25(9):1462\u20131469. \nhttps:\/\/doi.org\/10.1016\/j.euroneuro.2014.11.021","journal-title":"Eur Neuropsychopharmacol"},{"key":"5353_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neubiorev.2018.03.020","volume":"89","author":"E Galaj","year":"2018","unstructured":"Galaj E, Ewing S, Ranaldi R (2018) Dopamine D1 and D3 receptor polypharmacology as a potential treatment approach for substance use disorder. Neurosci Biobehav Rev 89:13\u201328. \nhttps:\/\/doi.org\/10.1016\/j.neubiorev.2018.03.020","journal-title":"Neurosci Biobehav Rev"},{"key":"5353_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.brainres.2016.05.027","volume":"1646","author":"A Gano","year":"2016","unstructured":"Gano A, Doremus-Fitzwater TL, Deak T (2016) Sustained alterations in neuroimmune gene expression after daily, but not intermittent, alcohol exposure. Brain Res 1646:62\u201372. \nhttps:\/\/doi.org\/10.1016\/j.brainres.2016.05.027","journal-title":"Brain Res"},{"issue":"12","key":"5353_CR29","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/j.1468-1331.2011.03593.x","volume":"19","author":"O Gershanik","year":"2012","unstructured":"Gershanik O, Jenner P (2012) Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson\u2019s disease. Eur J Neurol 19(12):1502\u20131508. \nhttps:\/\/doi.org\/10.1111\/j.1468-1331.2011.03593.x","journal-title":"Eur J Neurol"},{"issue":"10","key":"5353_CR30","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1007\/s12035-019-1564-8","volume":"56","author":"Xavier Guitart","year":"2019","unstructured":"Guitart, X., Moreno, E., Rea, W., Sanchez-Soto, M., Cai, N. S., Quiroz, C., . . . Ferre, S. (2019). Biased G protein-independent signaling of dopamine D1-D3 receptor heteromers in the nucleus accumbens. Mol Neurobiol doi:\nhttps:\/\/doi.org\/10.1007\/s12035-019-1564-8","journal-title":"Molecular Neurobiology"},{"issue":"4","key":"5353_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1124\/mol.114.093096","volume":"86","author":"X Guitart","year":"2014","unstructured":"Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sanchez-Soto M et al (2014) Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer. Mol Pharmacol 86(4):417\u2013429. \nhttps:\/\/doi.org\/10.1124\/mol.114.093096","journal-title":"Mol Pharmacol"},{"issue":"1\u20132","key":"5353_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0014-2999(02)01716-8","volume":"445","author":"RD Heijtz","year":"2002","unstructured":"Heijtz RD, Beraki S, Scott L, Aperia A, Forssberg H (2002) Sex differences in the motor inhibitory and stimulatory role of dopamine D1 receptors in rats. Eur J Pharmacol 445(1\u20132):97\u2013104","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"5353_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190\u2013199. \nhttps:\/\/doi.org\/10.1002\/mds.20324","journal-title":"Mov Disord"},{"issue":"4","key":"5353_CR34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mds.26947","volume":"32","author":"FL Hernandez","year":"2017","unstructured":"Hernandez FL, Castela I, Ruiz-DeDiego I, Obeso JA, Moratalla R (2017) Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. Mov Disord 32(4):530\u2013537. \nhttps:\/\/doi.org\/10.1002\/mds.26947","journal-title":"Mov Disord"},{"key":"5353_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.physbeh.2013.10.035","volume":"124","author":"CM Hueston","year":"2014","unstructured":"Hueston CM, Deak T (2014) The inflamed axis: the interaction between stress, hormones, and the expression of inflammatory-related genes within key structures comprising the hypothalamic-pituitary-adrenal axis. Physiol Behav 124:77\u201391. \nhttps:\/\/doi.org\/10.1016\/j.physbeh.2013.10.035","journal-title":"Physiol Behav"},{"key":"5353_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuropharm.2018.06.024","volume":"138","author":"K Lanza","year":"2018","unstructured":"Lanza K, Meadows SM, Chambers NE, Nuss E, Deak MM, Ferre S, Bishop C (2018) Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: implications for L-DOPA-induced dyskinesia. Neuropharmacology 138:304\u2013314. \nhttps:\/\/doi.org\/10.1016\/j.neuropharm.2018.06.024","journal-title":"Neuropharmacology"},{"key":"5353_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuroscience.2015.09.018","volume":"310","author":"D Lindenbach","year":"2015","unstructured":"Lindenbach D, Conti MM, Ostock CY, Dupre KB, Bishop C (2015) Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia. Neuroscience 310:12\u201326. \nhttps:\/\/doi.org\/10.1016\/j.neuroscience.2015.09.018","journal-title":"Neuroscience"},{"issue":"18","key":"5353_CR38","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1111\/bph.13937","volume":"174","author":"D Lindenbach","year":"2017","unstructured":"Lindenbach D, Das B, Conti MM, Meadows SM, Dutta AK, Bishop C (2017) D-512, a novel dopamine D2\/3 receptor agonist, demonstrates greater anti-parkinsonian efficacy than ropinirole in parkinsonian rats. Br J Pharmacol 174(18):3058\u20133071. \nhttps:\/\/doi.org\/10.1111\/bph.13937","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5353_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbr.2006.09.019","volume":"177","author":"HS Lindgren","year":"2007","unstructured":"Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA (2007) The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 177(1):150\u2013159. \nhttps:\/\/doi.org\/10.1016\/j.bbr.2006.09.019","journal-title":"Behav Brain Res"},{"issue":"1","key":"5353_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","volume":"15","author":"M Lundblad","year":"2002","unstructured":"Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease. Eur J Neurosci 15(1):120\u2013132","journal-title":"Eur J Neurosci"},{"issue":"3","key":"5353_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/JPD-2012-120103","volume":"2","author":"A Manson","year":"2012","unstructured":"Manson A, Stirpe P, Schrag A (2012) Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Park Dis 2(3):189\u2013198. \nhttps:\/\/doi.org\/10.3233\/JPD-2012-120103","journal-title":"J Park Dis"},{"issue":"38","key":"5353_CR42","doi-asserted-by":"publisher","first-page":"26016","DOI":"10.1074\/jbc.M710349200","volume":"283","author":"Daniel Marcellino","year":"2008","unstructured":"Marcellino D, Ferre S, Casado V, Cortes A, Le Foll B, Mazzola C et al (2008) Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283(38):26016\u201326025. \nhttps:\/\/doi.org\/10.1074\/jbc.M710349200","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"5353_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1124\/jpet.114.214833","volume":"350","author":"SE Martelle","year":"2014","unstructured":"Martelle SE, Nader SH, Czoty PW, John WS, Duke AN, Garg PK, Garg S, Newman AH, Nader MA (2014) Further characterization of quinpirole-elicited yawning as a model of dopamine D3 receptor activation in male and female monkeys. J Pharmacol Exp Ther 350(2):205\u2013211. \nhttps:\/\/doi.org\/10.1124\/jpet.114.214833","journal-title":"J Pharmacol Exp Ther"},{"key":"5353_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","volume":"286","author":"G Mulas","year":"2016","unstructured":"Mulas G, Espa E, Fenu S, Spiga S, Cossu G, Pillai E, Carboni E, Simbula G, Jad\u017ei\u0107 D, Angius F, Spolitu S, Batetta B, Lecca D, Giuffrida A, Carta AR (2016) Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson\u2019s disease. Exp Neurol 286:83\u201392. \nhttps:\/\/doi.org\/10.1016\/j.expneurol.2016.09.013","journal-title":"Exp Neurol"},{"key":"5353_CR45","doi-asserted-by":"publisher","first-page":"117957351772633","DOI":"10.1177\/1179573517726335","volume":"9","author":"GA Prieto","year":"2017","unstructured":"Prieto GA (2017) Abnormalities of dopamine D3 receptor signaling in the diseased brain. J Cent Nerv Syst Dis 9:1179573517726335. \nhttps:\/\/doi.org\/10.1177\/1179573517726335","journal-title":"J Cent Nerv Syst Dis"},{"issue":"2","key":"5353_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuroscience.2009.08.030","volume":"164","author":"GA Prieto","year":"2009","unstructured":"Prieto GA, Perez-Burgos A, Fiordelisio T, Salgado H, Galarraga E, Drucker-Colin R, Bargas J (2009) Dopamine D(2)-class receptor supersensitivity as reflected in Ca2+ current modulation in neostriatal neurons. Neuroscience 164(2):345\u2013350. \nhttps:\/\/doi.org\/10.1016\/j.neuroscience.2009.08.030","journal-title":"Neuroscience"},{"issue":"5","key":"5353_CR47","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1152\/jn.00516.2010","volume":"105","author":"GA Prieto","year":"2011","unstructured":"Prieto GA, Perez-Burgos A, Palomero-Rivero M, Galarraga E, Drucker-Colin R, Bargas J (2011) Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on Ca V 2.1 channels via PIP2 depletion. J Neurophysiol 105(5):2260\u20132274. \nhttps:\/\/doi.org\/10.1152\/jn.00516.2010","journal-title":"J Neurophysiol"},{"issue":"1","key":"5353_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nbd.2010.08.018","volume":"41","author":"C Rangel-Barajas","year":"2011","unstructured":"Rangel-Barajas C, Silva I, Lopez-Santiago LM, Aceves J, Erlij D, Floran B (2011) L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V\/VI and increased GABA release in the substantia nigra reticulata. Neurobiol Dis 41(1):51\u201361. \nhttps:\/\/doi.org\/10.1016\/j.nbd.2010.08.018","journal-title":"Neurobiol Dis"},{"issue":"2","key":"5353_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archneur.58.2.249","volume":"58","author":"O Rascol","year":"2001","unstructured":"Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WJ, Wright S (2001) Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58(2):249\u2013254","journal-title":"Arch Neurol"},{"issue":"1","key":"5353_CR50","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/cercor\/bhv231","volume":"27","author":"O Solis","year":"2015","unstructured":"Solis O, Garcia-Montes JR, Gonzalez-Granillo A, Xu M, Moratalla R (2015) Dopamine D3 receptor modulates l-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb Cortex 27(1):435\u2013446. \nhttps:\/\/doi.org\/10.1093\/cercor\/bhv231","journal-title":"Cereb Cortex"},{"issue":"8","key":"5353_CR51","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00702-018-1852-x","volume":"125","author":"O Solis","year":"2018","unstructured":"Solis O, Moratalla R (2018) Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia. J Neural Transm (Vienna) 125(8):1187\u20131194. \nhttps:\/\/doi.org\/10.1007\/s00702-018-1852-x","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"5353_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1586\/14737175.2015.1001747","volume":"15","author":"P Stathis","year":"2015","unstructured":"Stathis P, Konitsiotis S, Antonini A (2015) Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Rev Neurother 15(2):207\u2013213. \nhttps:\/\/doi.org\/10.1586\/14737175.2015.1001747","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"5353_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18\u201327. \nhttps:\/\/doi.org\/10.1002\/ana.22060","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"5353_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jns.2012.05.029","volume":"319","author":"DC Suh","year":"2012","unstructured":"Suh DC, Pahwa R, Mallya U (2012) Treatment patterns and associated costs with Parkinson\u2019s disease levodopa induced dyskinesia. J Neurol Sci 319(1\u20132):24\u201331. \nhttps:\/\/doi.org\/10.1016\/j.jns.2012.05.029","journal-title":"J Neurol Sci"},{"issue":"4","key":"5353_CR55","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.pbb.2005.06.013","volume":"81","author":"JL Taylor","year":"2005","unstructured":"Taylor JL, Bishop C, Walker PD (2005) Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 81(4):887\u2013893. \nhttps:\/\/doi.org\/10.1016\/j.pbb.2005.06.013","journal-title":"Pharmacol Biochem Behav"},{"key":"5353_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41531-018-0067-z","volume":"4","author":"N Titova","year":"2018","unstructured":"Titova N, Levin O, Katunina E, Ray Chaudhuri K (2018) \u2018Levodopa Phobia\u2019: a review of a not uncommon and consequential phenomenon. NPJ Parkinsons Dis 4:31. \nhttps:\/\/doi.org\/10.1038\/s41531-018-0067-z","journal-title":"NPJ Parkinsons Dis"},{"issue":"12","key":"5353_CR57","doi-asserted-by":"publisher","first-page":"e112287","DOI":"10.1371\/journal.pone.0112287","volume":"9","author":"CC Umeh","year":"2014","unstructured":"Umeh CC, Perez A, Augustine EF, Dhall R, Dewey RB Jr, Mari Z et al (2014) No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada\u2014baseline findings of a multicenter trial. PLoS One 9(12):e112287. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0112287","journal-title":"PLoS One"},{"issue":"7","key":"5353_CR58","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","volume":"62","author":"JE Westin","year":"2007","unstructured":"Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62(7):800\u2013810. \nhttps:\/\/doi.org\/10.1016\/j.biopsych.2006.11.032","journal-title":"Biol Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05353-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-019-05353-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05353-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:44Z","timestamp":1597881644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-019-05353-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5353"],"URL":"https:\/\/doi.org\/10.1007\/s00213-019-05353-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"4 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}